Snoop 0.1%, 15 ml nasal spray

The instruction for medical use of Snup Torgovoye medicine a name Snup Mezhdunarodnoye the unlicensed name Xylomethazolinum Dosage Form Spray of Nasal 0.05% and 0.1% Structure of 100 Ml of Spray contain active agent - xylomethazolinum a hydrochloride of 0.05 g or 0.1 g, excipients: potassium dihydrophosphate, water sea, the water purified. Description Transparent colourless solution Pharmacotherapeutic group Nasal drugs. Antikongestanta and other nasal drugs for topical administration. Sympathomimetics. Xylomethazolinum the ATX R01AA07 Code the Pharmacological Pharmacokinetics At properties intranasal use in the recommended doses is practically not soaked up. Approach of action is observed, as a rule, within 5-10 minutes and the dekongestantny effect proceeds on average 6-8 hours after single use. The pharmacodynamics Xylomethazolinum, derivative imidazoline, represents a sympathomimetic with alpha and adrenergic action. Being the agonist of alpha adrenoceptors of direct action which is not affecting beta adrenoceptors, xylomethazolinum has no indirect sympathomimetic effect implemented by Norepinephrinum release. Thanks to structural similarity of xylomethazolinum and Norepinephrinum, stimulation alfa-1 and alfa-2 receptors, caused by xylomethazolinum, conducts to vasoconstriction. It promotes reduction of hypostasis of mucous membranes and improvement of outflow of a secret that leads to simplification of nasal breath. The sterile isotonic sea water which is a part of drug promotes maintenance of the normal physiological state of a mucous membrane of a nasal cavity, reduces viscosity of a secret and normalizes its development by scyphoid cells of a mucous membrane of a nasal cavity, improves function of a ciliary epithelium that strengthens the resilience of a mucous membrane of a nasal cavity and adnexal bosoms to introduction of pathogenic bacteria and viruses. Besides, sea water promotes washing off and removal of allergens and haptens from mucous a nose, to reduction of local inflammatory process. Indications - rhinitis in acute respiratory diseases - allergic rhinitis - for improvement of outflow of a secret at inflammation of near-nasal bosoms and also in the catarrh of a middle ear connected with catarrhal diseases the Route of administration and doses Snup nasal spray of 0.05% to Children aged from 2 up to 6 years - on 1 injection in each nasal course 1-3 times a day. Snup, nasal spray of 0.1% to Adults and children is more senior than 6 years - on 1 injection in each nasal course 1-3 times a day. It is not necessary to use drug more often than 3 times a day. Duration of a course of treatment should not exceed 5-7 days. Side effects Often (≥1/100 - & lt, 1/10) - burning and xeromycteria, sneezing Infrequently (≥1/1000 - & lt, 1/100) - resuming of congestion of a nose after decrease in antiedematous action, nasal bleedings - allergic reactions (Quincke's disease, an itching, skin rashes) is rare (≥1/10000 - & lt, 1/1000) - heartbeat, tachycardia, increase in arterial blood pressure is Very rare (& lt, 1/10000) - arrhythmia - a headache, fatigue, drowsiness or insomnia, concern, sedation, spasms and hallucinations (mainly at children) - an apnoea (at children of younger age and newborns) Contraindications - hypersensitivity to active agent or any other component of drug - atrophic rhinitis - states after the transsphenoidal hypophysectomy or other surgical interventions affecting a firm meninx including in the anamnesis - pregnancy, the lactation period Snup, nasal spray of 0.05% - children's age up to 2 years Snup, nasal spray of 0.1% - children's age up to 6 years Medicinal interactions Simultaneous use Snup, the tricyclic antidepressants, inhibitors of a monoaminooxidase (MAO) of traniltsiprominovy type or other medicines causing hypertensia leads to increase in arterial blood pressure. It is necessary to avoid combined use Snup with these drugs. Special instructions With care Snup has to be used at the following states: - at the patients accepting the MAO inhibitors or other medicines capable to increase arterial blood pressure - with the increased intraocular pressure (especially in closed-angle glaucoma) - in a serious illness of a cardiovascular system (for example, coronary heart disease, hypertensia) - at a pheochromocytoma - at metabolic disturbances (for example, gipertireoidoz, diabetes) - at a porphyria - in prostate adenoma. It is not necessary to exceed the recommended daily dose of drug. Snup should not be applied more than 7 days without consultation of the doctor. Repeated use is possible only after a break in several days. Patients with chronic rhinitis can use drug only under observation of the doctor, in connection with risk of developing a mucosal atrophy of a nose. At prolonged use and/or overdose the reactive hyperemia of a mucous membrane of a nose which leads to narrowing of airways (phenomenon of ricochet) can develop. Development of chronic medicamentous rhinitis is a consequence of it that can lead to a nose mucosal atrophy. Treatment duration at children is defined by the doctor. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms At the correct use drug does not affect ability to run the vehicle or potentially dangerous mechanisms. Overdose Symptoms: concern, excitement, hallucinations, spasms, decrease in body temperature, a lethargy, drowsiness, a coma, a miosis, a mydriasis, the increased sweating, fever, pallor of integuments, cyanosis, nausea and vomiting, tachycardia, bradycardia, cardiac arrhythmia, cardiac arrest, palpitation, hypertensia, shocklike hypotonia, a fluid lungs, respiratory depression and an apnoea, mental disorders. After overdose, especially at children, symptoms often prevail from central nervous system (the including spasms and a coma), bradycardia, an apnoea and hypertensia which is replaced by hypotonia. Treatment: immediate purpose of a sorbent (activated carbon) orally, laxative or gastric lavage, if necessary hypotensive therapy (non-selective alpha adrenoblockers), symptomatic therapy. If necessary febrifugal, anticonvulsants, oxygen. At heavy overdose the intensive care in the conditions of a hospital is shown. Prescribing of vasoconstrictive drugs is contraindicated. A form of release and packing On 15 ml of drug in a polyethylene bottle with the raspylitelny valve. On 1 bottle together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. To Store storage conditions at a temperature not over 25 ºС. To store out of children's reach! 3 years not to apply a period of storage after an expiration date. A period of storage after the first opening of a bottle – 12 months. Prescription status Without prescription the Producer / Packer of Famar Health Care Services Madrid S.A.U, Leganes Avenue 62, Alkorkon, 28923 Madrid, Spain the Owner of the registration certificate of STADA Artsnaymittel AG, Stadastrasse 2-18, D-61118 Bud Vilbel, Germany, the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) of DO LLP Nizhpharm Kazakhstan 050054, Republic of Kazakhstan, Almaty, Suyunbaya 162 A Ave.